Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Acute Kidney Injury | Research

Absence of long-term changes in urine biomarkers after AKI: findings from the CRIC study

Authors: Ian E. McCoy, Jesse Y. Hsu, Joseph V. Bonventre, Chirag R. Parikh, Alan S. Go, Kathleen D. Liu, Ana C. Ricardo, Anand Srivastava, Debbie L. Cohen, Jiang He, Jing Chen, Panduranga S. Rao, Anthony N. Muiru, Chi-yuan Hsu

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Mechanisms by which AKI leads to CKD progression remain unclear. Several urine biomarkers have been identified as independent predictors of progressive CKD. It is unknown whether AKI may result in long-term changes in these urine biomarkers, which may mediate the effect of AKI on CKD progression.

Methods

We selected 198 episodes of hospitalized AKI (defined as peak/nadir inpatient serum creatinine values ≥ 1.5) among adult participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. We matched the best non-AKI hospitalization (unique patients) for each AKI hospitalization using pre-hospitalization characteristics including eGFR and urine protein/creatinine ratio. Biomarkers were measured in banked urine samples collected at annual CRIC study visits.

Results

Urine biomarker measurements occurred a median of 7 months before and 5 months after hospitalization. There were no significant differences in the change in urine biomarker-to-creatinine ratio between the AKI and non-AKI groups: KIM-1/Cr + 9% vs + 7%, MCP-1/Cr + 4% vs + 1%, YKL-40/Cr + 7% vs -20%, EGF/Cr -11% vs -8%, UMOD/Cr -2% vs -7% and albumin/Cr + 17% vs + 13% (all p > 0.05).

Conclusion

In this cohort of adults with CKD, AKI did not associate with long-term changes in urine biomarkers.
Appendix
Available only for authorised users
Literature
1.
Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, et al. World incidence of AKI: A meta-analysis. Clin J Am Soc Nephrol. 2013;8(9):1482–93.PubMedPubMedCentralCrossRef
2.
Al-Jaghbeer M, Dealmeida D, Bilderback A, Ambrosino R, Kellum JA. Clinical Decision Support for In-Hospital AKI. J Am Soc Nephrol. 2018;29(2):654–60.PubMedCrossRef
3.
Heung M, Steffick DE, Zivin K, Gillespie BW, Banerjee T, Hsu CY, et al. Acute Kidney Injury Recovery Pattern and Subsequent Risk of CKD: An Analysis of Veterans Health Administration Data. Am J Kidney Dis. 2016;67(5):742–52.PubMedCrossRef
4.
Hsu CY, Chertow GM, McCulloch CE, Fan D, Ordoñez JD, Go AS. Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol. 2009;4(5):891–8.PubMedPubMedCentralCrossRef
5.
Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordõez JD, et al. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int. 2009;76(8):893–9.PubMedPubMedCentralCrossRef
6.
James MT, Hemmelgarn BR, Wiebe N, Pannu N, Manns BJ, Klarenbach SW, et al. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: A cohort study. Lancet. 2010;376(9758):2096–103.PubMedCrossRef
7.
Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: A systematic review and meta-analysis. Kidney Int. 2012;81(5):442–8.PubMedCrossRef
8.
Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20(1):223–8.PubMedPubMedCentralCrossRef
9.
See EJ, Jayasinghe K, Glassford N, Bailey M, Johnson DW, Polkinghorne KR, et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int. 2019;95(1):160–72.PubMedCrossRef
10.
Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018;14(10):607–25.PubMedCrossRef
11.
Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK. Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol. 2015;26(8):1765–76.PubMedPubMedCentralCrossRef
12.
James MT, Ghali WA, Tonelli M, Faris P, Knudtson ML, Pannu N, et al. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int. 2010;78(8):803–9.PubMedCrossRef
13.
Hsu RK, Hsu CY, McCulloch CE, Yang J, Anderson AH, Chen J, et al. Research-based versus clinical serum creatinine measurements and the association of acute kidney injury with subsequent kidney function: Findings from the Chronic Renal Insufficiency Cohort study. Clin Kidney J. 2019;13(1):55–62.PubMedPubMedCentralCrossRef
14.
Greenberg JH, Abraham AG, Xu Y, Schelling JR, Feldman HI, Sabbisetti VS, et al. Urine biomarkers of kidney tubule health, injury, and inflammation are associated with progression of CKD in children. J Am Soc Nephrol. 2021;32(10):2664–77.PubMedCrossRef
15.
Malhotra R, Katz R, Jotwani V, Ambrosius WT, Raphael KL, Haley W, et al. Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD. Clin J Am Soc Nephrol. 2020;15:349–58.PubMedPubMedCentralCrossRef
16.
Puthumana J, Thiessen-Philbrook H, Xu L, Coca SG, Garg AX, Himmelfarb J, et al. Biomarkers of inflammation and repair in kidney disease progression. J Clin Invest. 2021;131(3):e139927.PubMedCentralCrossRef
17.
Satirapoj B, Dispan R, Radinahamed P, Kitiyakara C. Urinary epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors for rapid loss of renal function in type 2 diabetic patients with diabetic kidney disease. BMC Nephrol. 2018;19(1):1–10.CrossRef
18.
Jotwani V, Garimella PS, Katz R, Malhotra R, Bates J, Cheung AK, et al. Tubular Biomarkers and Chronic Kidney Disease Progression in SPRINT Participants. Am J Nephrol. 2020;51(10):797–805.PubMedCrossRef
19.
Hsu CY, Chinchilli VM, Coca S, Devarajan P, Ghahramani N, Go AS, et al. Post-Acute Kidney Injury Proteinuria and Subsequent Kidney Disease Progression: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study. JAMA Intern Med. 2020;180(3):402–10.PubMedPubMedCentralCrossRef
20.
Cooper DS, Claes D, Goldstein SL, Bennett MR, Ma Q, Devarajan P, et al. Follow-up renal assessment of injury long-term after acute kidney injury (FRAIL-AKI). Clin J Am Soc Nephrol. 2016;11(1):21–9.PubMedCrossRef
21.
Shinke H, Masuda S, Togashi Y, Ikemi Y, Ozawa A, Sato T, et al. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol. 2015;76(5):989–96.PubMedPubMedCentralCrossRef
22.
Bullen AL, Katz R, Lee AK, Anderson CAM, Cheung AK, Garimella PS, et al. The SPRINT trial suggests that markers of tubule cell function in the urine associate with risk of subsequent acute kidney injury while injury markers elevate after the injury. Kidney Int. 2019;96(2):470–9.PubMedPubMedCentralCrossRef
23.
Taira T, Yoshimura A, Lizuka K, Iwasaki S, Ideura T, Koshikawa S. Urinary Epidermal Growth Factor Levels in Patients With Acute Renal Failure. Am J Kidney Dis. 1993;22(5):656–61.PubMedCrossRef
24.
Hsu CY, Hsu RK, Liu KD, Yang J, Anderson A, Chen J, et al. Impact of AKI on urinary protein excretion: Analysis of two prospective cohorts. J Am Soc Nephrol. 2019;30(7):1271–81.PubMedPubMedCentralCrossRef
25.
McCoy IE, Hsu JY, Bonventre JV, Parikh CR, Go AS, Liu KD, et al. Acute Kidney Injury Associates with Long-Term Increases in Plasma TNFR1, TNFR2, and KIM-1: Findings from the CRIC Study. J Am Soc Nephrol. 2022;33(6):1173–81.PubMedCrossRef
26.
Hannan M, Ansari S, Meza N, Anderson AH, Srivastava A, Waikar S, et al. Risk factors for CKD progression: overview of findings from the CRIC study. Clin J Am Soc Nephrol. 2021;16(4):648–59.PubMedCrossRef
27.
Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–138.
28.
Lin J, Fernandez H, Shashaty MGS, Negoianu D, Testani JM, Berns JS, et al. False-positive rate of AKI using consensus creatinine–based criteria. Clin J Am Soc Nephrol. 2015;10(10):1723–31.PubMedPubMedCentralCrossRef
29.
Sabbisetti VS, Waikar SS, Antoine DJ, Smiles A, Wang C, Ravisankar A, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol. 2014;25(10):2177–86.PubMedPubMedCentralCrossRef
30.
Nadkarni GN, Rao V, Ismail-Beigi F, Fonseca VA, Shah SV, Simonson MS, et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD trial. Clin J Am Soc Nephrol. 2016;11(8):1343–52.PubMedPubMedCentralCrossRef
31.
Coca SG, Nadkarni GN, Huang Y, Moledina DG, Rao V, Zhang J, et al. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol. 2017;28(9):2786–93.PubMedPubMedCentralCrossRef
32.
Colombo M, McGurnaghan SJ, Blackbourn LAK, Dalton RN, Dunger D, Bell S, et al. Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. Diabetologia. 2020;63(4):788–98.PubMedPubMedCentralCrossRef
33.
Greenberg JH, Abraham AG, Xu Y, Schelling JR, Feldman HI, Sabbisetti VS, et al. Plasma biomarkers of tubular injury and inflammation are associated with CKD progression in children. J Am Soc Nephrol. 2020;31:1067–77.PubMedPubMedCentralCrossRef
34.
Pena MJ, Heinzel A, Heinze G, Alkhalaf A, Bakker SJL, Nguyen TQ, et al. A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes. PLoS ONE. 2015;10(5):1–16.CrossRef
35.
36.
37.
Hawari FI, Rouhani FN, Cui X, Yu ZX, Buckley C, Kaler M, et al. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: A mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci U S A. 2004;101(5):1297–302.PubMedPubMedCentralCrossRef
38.
39.
Nowak N, Skupien J, Niewczas MA, Yamanouchi M, Major M, Croall S, et al. Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int. 2016;89(2):459–67.PubMedPubMedCentralCrossRef
40.
Bhatraju PK, Zelnick LR, Shlipak M, Katz R, Kestenbaum B. Association of soluble TNFR-1 concentrations with long-term decline in kidney function: The multi-ethnic study of atherosclerosis. J Am Soc Nephrol. 2018;29(11):2713–21.PubMedPubMedCentralCrossRef
41.
Colombo M, Valo E, McGurnaghan SJ, Sandholm N, Blackbourn LAK, Dalton RN, et al. Biomarker panels associated with progression of renal disease in type 1 diabetes. Diabetologia. 2019;62(9):1616–27.PubMedPubMedCentralCrossRef
42.
Puthumana J, Hall IE, Reese PP, Schröppel B, Weng FL, Thiessen-Philbrook H, et al. YKL-40 associates with renal recovery in deceased donor kidney transplantation. J Am Soc Nephrol. 2017;28(2):661–70.PubMedCrossRef
43.
Menez S, Moledina DG, Thiessen-Philbrook H, Wilson FP, Obeid W, Simonov M, et al. Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19. Am J Kidney Dis. 2021;79(2):257–67.
44.
Menez S, Ju W, Menon R, Moledina DG, Philbrook HT, McArthur E, et al. Urinary EGF and MCP-1 and risk of CKD after cardiac surgery. JCI Insight. 2021;6(11):e147464.PubMedCentral
45.
Grams ME, Waikar SS, MacMahon B, Whelton S, Ballew SH, Coresh J. Performance and limitations of administrative data in the identification of AKI. Clin J Am Soc Nephrol. 2014;9(4):682–9.PubMedPubMedCentralCrossRef
46.
47.
Nadkarni GN, Chauhan K, Rao V, Ix JH, Shlipak MG, Parikh CR, et al. Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants. Am J Kidney Dis. 2019;73(1):31–8.PubMedCrossRef
Metadata
Title
Absence of long-term changes in urine biomarkers after AKI: findings from the CRIC study
Authors
Ian E. McCoy
Jesse Y. Hsu
Joseph V. Bonventre
Chirag R. Parikh
Alan S. Go
Kathleen D. Liu
Ana C. Ricardo
Anand Srivastava
Debbie L. Cohen
Jiang He
Jing Chen
Panduranga S. Rao
Anthony N. Muiru
Chi-yuan Hsu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02937-x

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue

Research

Cephalic arch restenosis rates in hemodialysis patients with brachiocephalic fistulae: a retrospective multicenter analysis of 3301 patients

Case report

A case report of atypical anti-glomerular basement membrane disease

Study protocol

Treatment of early borderline lesions in low immunological risk kidney transplant patients: a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study

Case report

One case of arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome featuring an incomplete and mild phenotype

Research

Adherence to hemodialysis and medical regimens among patients with end-stage renal disease during COVID-19 pandemic: a cross-sectional study

Research

Association of serum 25-hydroxy vitamin D with gait speed and handgrip strength in patients on hemodialysis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits